Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Long-Term Investments for 6 consecutive years, with $155.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 40.34% to $155.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $155.2 million through Dec 2025, down 40.34% year-over-year, with the annual reading at $155.2 million for FY2025, 40.34% down from the prior year.
  • Long-Term Investments for Q4 2025 was $155.2 million at Intellia Therapeutics, up from $22.5 million in the prior quarter.
  • The five-year high for Long-Term Investments was $350.5 million in Q3 2021, with the low at $10.0 million in Q4 2023.
  • Average Long-Term Investments over 5 years is $81.1 million, with a median of $32.6 million recorded in 2022.
  • The sharpest move saw Long-Term Investments tumbled 94.14% in 2022, then skyrocketed 2502.15% in 2024.
  • Over 5 years, Long-Term Investments stood at $58.1 million in 2021, then increased by 19.28% to $69.3 million in 2022, then plummeted by 85.58% to $10.0 million in 2023, then surged by 2502.15% to $260.2 million in 2024, then tumbled by 40.34% to $155.2 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $155.2 million, $22.5 million, and $22.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.